董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| George Ng | 男 | Chief Executive Officer and Director | 52 | 67.33万美元 | 2.11 | 2026-06-01 |
| Khoso Baluch | 男 | Director | 68 | 10.00万美元 | 0.38 | 2026-06-01 |
| Justin Yorke | 男 | Chairman of the Board and Director | 60 | 10.00万美元 | 0.41 | 2026-06-01 |
| Geraldine Pannu | 女 | Director | 56 | 10.00万美元 | 0.36 | 2026-06-01 |
| James Neal | 男 | Director | 70 | 10.00万美元 | 0.23 | 2026-06-01 |
| David Young | 男 | Director and President of Research and Development | 73 | 30.54万美元 | 2.73 | 2026-06-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| George Ng | 男 | Chief Executive Officer and Director | 52 | 67.33万美元 | 2.11 | 2026-06-01 |
| Patrick Lin | 男 | Chief Business and Strategy Officer | 60 | 104.28万美元 | 1.37 | 2026-06-01 |
| Wendy Guy | 女 | Chief Administrative Officer | 61 | 101.98万美元 | 1.04 | 2026-06-01 |
| Russell Skibsted | 男 | Chief Financial Officer | 66 | 56.68万美元 | 1.16 | 2026-06-01 |
| David Young | 男 | Director and President of Research and Development | 73 | 30.54万美元 | 2.73 | 2026-06-01 |
董事简历
中英对照 | 中文 | 英文- George Ng
-
George Ng，自2020年2月起担任Legacy TuHURA董事，并在Kintara Merger合并完成后被任命为TuHURA董事会董事。Ng先生自2019年10月起担任Calidi Biotherapeutics， Inc. （NYSE American： CLDI）的董事，自2022年2月1日起担任其总裁兼首席运营官，以及自2023年8月8日起担任Processa Pharmaceuticals， Inc. （Nasdaq： PCSA）的董事兼首席执行官。此外，他目前是PENG Life Science Ventures的合伙人（2013年9月以来），IACTA Pharmaceuticals, Inc.的董事、联合创始人和首席商务官（2020年1月以来）。他的经验还包括在多家上市和私人全球生物技术和制药公司担任各种高管职位。Ng先生此前于2019年5月至2020年4月担任Inflammatory Response Research， Inc.董事，2019年7月至2020年1月担任Invent Medical Corp董事，2016年6月至2019年担任ImmuneOncia Therapeutics Inc.董事，并于2017年4月至2019年4月担任Virttu Biologics Limited董事。2015年3月至2019年4月，Ng先生还担任Sorrento Therapeutics， Inc.（纳斯达克股票代码：SRNE）的执行副总裁兼首席行政官；2012年9月至2019年4月，担任Scilex Pharmaceuticals Inc.的联合创始人兼业务总裁；2012年12月至2015年3月，担任BioDelivery Sciences International Inc.（纳斯达克股票代码：BDSI）的高级副总裁兼总法律顾问。他持有Notre Dame大学School of Law的法学博士学位，以及California大学， Davis的生物化学和经济学双学位。
George Ng has served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer and as a director since August 8, 2023. He has served as a member of the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi") from October 2019 to September 2024, and was Calidi's President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science Ventures since September 2013; a member of the board of directors and co founder at IACTA Pharmaceuticals, Inc. since January 2020; and member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020. His experience further includes serving in various executive level or board of director positions for multiple publicly traded and private global biotechnology and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co Founder and President, Business of Scilex Pharmaceuticals Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc. (Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis. - George Ng，自2020年2月起担任Legacy TuHURA董事，并在Kintara Merger合并完成后被任命为TuHURA董事会董事。Ng先生自2019年10月起担任Calidi Biotherapeutics， Inc. （NYSE American： CLDI）的董事，自2022年2月1日起担任其总裁兼首席运营官，以及自2023年8月8日起担任Processa Pharmaceuticals， Inc. （Nasdaq： PCSA）的董事兼首席执行官。此外，他目前是PENG Life Science Ventures的合伙人（2013年9月以来），IACTA Pharmaceuticals, Inc.的董事、联合创始人和首席商务官（2020年1月以来）。他的经验还包括在多家上市和私人全球生物技术和制药公司担任各种高管职位。Ng先生此前于2019年5月至2020年4月担任Inflammatory Response Research， Inc.董事，2019年7月至2020年1月担任Invent Medical Corp董事，2016年6月至2019年担任ImmuneOncia Therapeutics Inc.董事，并于2017年4月至2019年4月担任Virttu Biologics Limited董事。2015年3月至2019年4月，Ng先生还担任Sorrento Therapeutics， Inc.（纳斯达克股票代码：SRNE）的执行副总裁兼首席行政官；2012年9月至2019年4月，担任Scilex Pharmaceuticals Inc.的联合创始人兼业务总裁；2012年12月至2015年3月，担任BioDelivery Sciences International Inc.（纳斯达克股票代码：BDSI）的高级副总裁兼总法律顾问。他持有Notre Dame大学School of Law的法学博士学位，以及California大学， Davis的生物化学和经济学双学位。
- George Ng has served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer and as a director since August 8, 2023. He has served as a member of the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi") from October 2019 to September 2024, and was Calidi's President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science Ventures since September 2013; a member of the board of directors and co founder at IACTA Pharmaceuticals, Inc. since January 2020; and member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020. His experience further includes serving in various executive level or board of director positions for multiple publicly traded and private global biotechnology and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co Founder and President, Business of Scilex Pharmaceuticals Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc. (Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis.
- Khoso Baluch
-
Khoso Baluch自2022年7月起担任董事。他在全球各地区的生物制药行业拥有超过36年的经验。他在美国私营公司Relevant Bio任职，自2024年2月起担任董事会成员，在美国上市公司Longeveron任职，自2023年6月起担任董事会成员。自2012年起，他担任法国上市生物技术公司Poxel S.A.（OTC：PXXLF）的独立董事，并担任其薪酬委员会主席，并于2023年3月成为主席。他还在2021年12月至2022年11月期间担任法国私人控股公司Da Volterra的董事会主席。2016年至2021年，Baluch先生担任CorMedix，Inc.（纳斯达克：CRMD）的首席执行官和董事会成员，该公司是一家美国上市制药公司。Baluch先生还在2008年1月至2016年4月期间在UCB，S.A.担任过多个高级职位，包括高级副总裁兼欧洲、中东和非洲总裁。在加入UCB之前，Baluch先生曾在礼来公司（NYSE：LLY）工作了24年，在一般管理、业务发展、市场准入和产品领导方面担任横跨欧洲、中东和美国的国际职务。Baluch先生拥有伦敦城市大学航空工程学士学位和克兰菲尔德管理学院MBA学位。
Khoso Baluch has served as a director since July 2022. He has over 36 years of experience across global geographies in the biopharmaceutical industry. He serves on Relevant Bio, a private US company, as a member of the board of directors since February 2024 and Longeveron, a US public company, as a member of the board of directors since June 2023. Since 2012, he has served as an independent director of Poxel S.A. (OTC: PXXLF), a French publicly traded biotech company, and chairs its compensation committee and as of March 2023 became Chairman. He also served as the Chairman of the Board for Da Volterra, a French privately held company, from December 2021 until November 2022. From 2016 to 2021, Mr. Baluch served as the Chief Executive Officer and a member of the board of directors of CorMedix, Inc. (Nasdaq: CRMD), a publicly traded pharmaceutical company in the United States. Mr. Baluch also held various senior positions at UCB, S.A. between January 2008 to April 2016, including Senior Vice President and President Europe, Middle East & Africa. Prior to joining UCB, Mr. Baluch worked for Eli Lilly and Company (NYSE: LLY) for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. Mr. Baluch holds a B.S. in Aeronautical Engineering from City University London and an MBA from Cranfield School of Management. - Khoso Baluch自2022年7月起担任董事。他在全球各地区的生物制药行业拥有超过36年的经验。他在美国私营公司Relevant Bio任职，自2024年2月起担任董事会成员，在美国上市公司Longeveron任职，自2023年6月起担任董事会成员。自2012年起，他担任法国上市生物技术公司Poxel S.A.（OTC：PXXLF）的独立董事，并担任其薪酬委员会主席，并于2023年3月成为主席。他还在2021年12月至2022年11月期间担任法国私人控股公司Da Volterra的董事会主席。2016年至2021年，Baluch先生担任CorMedix，Inc.（纳斯达克：CRMD）的首席执行官和董事会成员，该公司是一家美国上市制药公司。Baluch先生还在2008年1月至2016年4月期间在UCB，S.A.担任过多个高级职位，包括高级副总裁兼欧洲、中东和非洲总裁。在加入UCB之前，Baluch先生曾在礼来公司（NYSE：LLY）工作了24年，在一般管理、业务发展、市场准入和产品领导方面担任横跨欧洲、中东和美国的国际职务。Baluch先生拥有伦敦城市大学航空工程学士学位和克兰菲尔德管理学院MBA学位。
- Khoso Baluch has served as a director since July 2022. He has over 36 years of experience across global geographies in the biopharmaceutical industry. He serves on Relevant Bio, a private US company, as a member of the board of directors since February 2024 and Longeveron, a US public company, as a member of the board of directors since June 2023. Since 2012, he has served as an independent director of Poxel S.A. (OTC: PXXLF), a French publicly traded biotech company, and chairs its compensation committee and as of March 2023 became Chairman. He also served as the Chairman of the Board for Da Volterra, a French privately held company, from December 2021 until November 2022. From 2016 to 2021, Mr. Baluch served as the Chief Executive Officer and a member of the board of directors of CorMedix, Inc. (Nasdaq: CRMD), a publicly traded pharmaceutical company in the United States. Mr. Baluch also held various senior positions at UCB, S.A. between January 2008 to April 2016, including Senior Vice President and President Europe, Middle East & Africa. Prior to joining UCB, Mr. Baluch worked for Eli Lilly and Company (NYSE: LLY) for 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, business development, market access and product leadership. Mr. Baluch holds a B.S. in Aeronautical Engineering from City University London and an MBA from Cranfield School of Management.
- Justin Yorke
-
Justin Yorke现任董事长，自2022年7月11日起担任该职务，自2017年8月起担任董事。Yorke先生作为投资基金和投资银行的机构股票基金经理和高级金融分析师，拥有超过25年的经验。20多年来，他一直是Arroyo Capital Management的合伙人，该公司管理着Richland基金，该基金的主要活动是投资美国的上市公司和私营公司。自2020年3月起，Yorke先生担任Splash Beverage集团股份有限公司（纽约证券交易所代码：SBEV）的董事兼公司秘书。从2006年到2007年，Yorke先生担任Jed Oil的非执行董事长和JMG Exploration的董事/首席执行官。2000年至2004年，他是位于旧金山的Asiatic Investment Management的合伙人。从1997年到2000年，Yorke先生在瑞士私人银行Darier Henstch，S.A.担任基金经理和高级金融分析师，常驻香港，在那里他管理着他们4亿美元的亚洲投资组合。从1995年到1997年，Yorke先生担任Peregrine Asset Management的助理董事和高级金融分析师，该公司是亚洲区域投资银行Peregrine Securities的一个部门。从1990年到1995年，Yorke先生担任瑞士私人银行Unifund Global Ltd.的副总裁兼高级金融分析师，担任其1.5亿美元亚洲投资组合的经理。Yorke先生拥有加州大学洛杉矶分校的学士学位。
Justin Yorke is currently the Chairman of the Board, a position he has held since July 11, 2022, and has served as a director since August 2017. Mr. Yorke has over 25 years of experience as an institutional equity fund manager and senior financial analyst for investment funds and investment banks. For more than 20 years, he has been a partner at Arroyo Capital Management which manages the Richland Fund whose primary activity is investing in public and private companies in the United States. Since March 2020, Mr. Yorke has served as a director and Corporate Secretary of Splash Beverage Group, Inc (NYSE:SBEV). From 2006 to 2007, Mr. Yorke served as non executive Chairman of Jed Oil and a director/CEO at JMG Exploration. From 2000 to 2004, he was a partner at Asiatic Investment Management, based in San Francisco. From 1997 to 2000, Mr. Yorke was a Fund Manager and Senior Financial Analyst, based in Hong Kong, for Darier Henstch, S.A., a private Swiss bank, where he managed their $400 million Asian investment portfolio. From 1995 to 1997, Mr. Yorke was an Assistant Director and Senior Financial Analyst with Peregrine Asset Management, which was a unit of Peregrine Securities, a regional Asian investment bank. From 1990 to 1995, Mr. Yorke was a Vice President and Senior Financial Analyst with Unifund Global Ltd., a private Swiss Bank, as a manager of its $150 million Asian investment portfolio. Mr. Yorke has a B.A. from the University of California, Los Angeles. - Justin Yorke现任董事长，自2022年7月11日起担任该职务，自2017年8月起担任董事。Yorke先生作为投资基金和投资银行的机构股票基金经理和高级金融分析师，拥有超过25年的经验。20多年来，他一直是Arroyo Capital Management的合伙人，该公司管理着Richland基金，该基金的主要活动是投资美国的上市公司和私营公司。自2020年3月起，Yorke先生担任Splash Beverage集团股份有限公司（纽约证券交易所代码：SBEV）的董事兼公司秘书。从2006年到2007年，Yorke先生担任Jed Oil的非执行董事长和JMG Exploration的董事/首席执行官。2000年至2004年，他是位于旧金山的Asiatic Investment Management的合伙人。从1997年到2000年，Yorke先生在瑞士私人银行Darier Henstch，S.A.担任基金经理和高级金融分析师，常驻香港，在那里他管理着他们4亿美元的亚洲投资组合。从1995年到1997年，Yorke先生担任Peregrine Asset Management的助理董事和高级金融分析师，该公司是亚洲区域投资银行Peregrine Securities的一个部门。从1990年到1995年，Yorke先生担任瑞士私人银行Unifund Global Ltd.的副总裁兼高级金融分析师，担任其1.5亿美元亚洲投资组合的经理。Yorke先生拥有加州大学洛杉矶分校的学士学位。
- Justin Yorke is currently the Chairman of the Board, a position he has held since July 11, 2022, and has served as a director since August 2017. Mr. Yorke has over 25 years of experience as an institutional equity fund manager and senior financial analyst for investment funds and investment banks. For more than 20 years, he has been a partner at Arroyo Capital Management which manages the Richland Fund whose primary activity is investing in public and private companies in the United States. Since March 2020, Mr. Yorke has served as a director and Corporate Secretary of Splash Beverage Group, Inc (NYSE:SBEV). From 2006 to 2007, Mr. Yorke served as non executive Chairman of Jed Oil and a director/CEO at JMG Exploration. From 2000 to 2004, he was a partner at Asiatic Investment Management, based in San Francisco. From 1997 to 2000, Mr. Yorke was a Fund Manager and Senior Financial Analyst, based in Hong Kong, for Darier Henstch, S.A., a private Swiss bank, where he managed their $400 million Asian investment portfolio. From 1995 to 1997, Mr. Yorke was an Assistant Director and Senior Financial Analyst with Peregrine Asset Management, which was a unit of Peregrine Securities, a regional Asian investment bank. From 1990 to 1995, Mr. Yorke was a Vice President and Senior Financial Analyst with Unifund Global Ltd., a private Swiss Bank, as a manager of its $150 million Asian investment portfolio. Mr. Yorke has a B.A. from the University of California, Los Angeles.
- Geraldine Pannu
-
Geraldine Pannu自2020年2月13日起担任董事。自2022年5月起，她还在皇家商业银行（纳斯达克：RBB）董事会担任独立董事。潘奴女士在投资和财务管理、基金运营、咨询和市场营销方面拥有超过25年的经验。自2020年1月以来，她一直是GLTJ Pioneer Capital的创始和管理合伙人，该公司专门从事旧金山湾区多户家庭、学生和老年住房的土地收购、权利和垂直开发。2018年9月至2019年9月，杰拉尔丁担任加利福尼亚湾区领先的投资基金公司Golden Gate Global（GGG）的业务发展董事总经理。在此期间，她还是金色财富管理集团（GWMG）的总裁，该集团是GGG的关联公司，为高净值个人和家庭提供专业的财富管理服务。2007年3月至2016年12月，潘努女士担任领先的对冲和风险投资基金公司ChinaRock Capital Management的首席运营官和管理合伙人。她此前曾任职于麦肯锡公司，Monitor Company，担任管理顾问。她已成功为多个对冲、风险投资和房地产基金筹集资金。她还帮助初创公司扩大业务类别和客户垂直领域并使其多样化，并增加收入。潘奴女士出生于上海，在香港长大。她获得了香港中文大学的工商管理硕士学位和哈佛商学院的工商管理硕士学位。她精通英语、普通话、广东话和上海话。
Geraldine Pannu has served as a director since February 13, 2020. Since May 2022, she has also served as an independent director on the Board of Royal Business Bank (Nasdaq: RBB). Ms. Pannu has over 25 years of experience in investment and financial management, fund operations, consulting and marketing. Since January 2020, she has been the Founding and Managing Partner of GLTJ Pioneer Capital, a firm that specializes in land acquisition, entitlement and vertical development of multifamily, student and senior housing in the San Francisco Bay Area. From September 2018 to September 2019, Geraldine was the Managing Director of Business Development for Golden Gate Global (GGG), a leading investment fund company in the Bay Area, CA. During this time, she was also the President of Golden Wealth Management Group (GWMG), an affiliated company of GGG that provides professional wealth management services to high net worth individuals and families. From March 2007 to December 2016, Ms. Pannu was the COO and Managing Partner for ChinaRock Capital Management, a leading hedge and venture capital fund company. She previously worked at McKinsey & Co., Monitor Company as a management consultant. She has successfully raised capital for several hedge, venture capital and real estate funds. She also helped start up companies expand and diversify business categories and client verticals and grow revenue. Ms. Pannu was born in Shanghai and grew up in Hong Kong. She received her BBA from the Chinese University of Hong Kong and an MBA from Harvard Business School. She is fluent in English, Mandarin, Cantonese and Shanghainese. - Geraldine Pannu自2020年2月13日起担任董事。自2022年5月起，她还在皇家商业银行（纳斯达克：RBB）董事会担任独立董事。潘奴女士在投资和财务管理、基金运营、咨询和市场营销方面拥有超过25年的经验。自2020年1月以来，她一直是GLTJ Pioneer Capital的创始和管理合伙人，该公司专门从事旧金山湾区多户家庭、学生和老年住房的土地收购、权利和垂直开发。2018年9月至2019年9月，杰拉尔丁担任加利福尼亚湾区领先的投资基金公司Golden Gate Global（GGG）的业务发展董事总经理。在此期间，她还是金色财富管理集团（GWMG）的总裁，该集团是GGG的关联公司，为高净值个人和家庭提供专业的财富管理服务。2007年3月至2016年12月，潘努女士担任领先的对冲和风险投资基金公司ChinaRock Capital Management的首席运营官和管理合伙人。她此前曾任职于麦肯锡公司，Monitor Company，担任管理顾问。她已成功为多个对冲、风险投资和房地产基金筹集资金。她还帮助初创公司扩大业务类别和客户垂直领域并使其多样化，并增加收入。潘奴女士出生于上海，在香港长大。她获得了香港中文大学的工商管理硕士学位和哈佛商学院的工商管理硕士学位。她精通英语、普通话、广东话和上海话。
- Geraldine Pannu has served as a director since February 13, 2020. Since May 2022, she has also served as an independent director on the Board of Royal Business Bank (Nasdaq: RBB). Ms. Pannu has over 25 years of experience in investment and financial management, fund operations, consulting and marketing. Since January 2020, she has been the Founding and Managing Partner of GLTJ Pioneer Capital, a firm that specializes in land acquisition, entitlement and vertical development of multifamily, student and senior housing in the San Francisco Bay Area. From September 2018 to September 2019, Geraldine was the Managing Director of Business Development for Golden Gate Global (GGG), a leading investment fund company in the Bay Area, CA. During this time, she was also the President of Golden Wealth Management Group (GWMG), an affiliated company of GGG that provides professional wealth management services to high net worth individuals and families. From March 2007 to December 2016, Ms. Pannu was the COO and Managing Partner for ChinaRock Capital Management, a leading hedge and venture capital fund company. She previously worked at McKinsey & Co., Monitor Company as a management consultant. She has successfully raised capital for several hedge, venture capital and real estate funds. She also helped start up companies expand and diversify business categories and client verticals and grow revenue. Ms. Pannu was born in Shanghai and grew up in Hong Kong. She received her BBA from the Chinese University of Hong Kong and an MBA from Harvard Business School. She is fluent in English, Mandarin, Cantonese and Shanghainese.
- James Neal
-
James Neal自2022年7月起担任董事。他在全球范围内形成并最大限度地扩大业务和技术合作以及将新颖的产品和技术推向市场方面拥有超过25年的经验。Neal先生自2016年12月起担任XOMA公司（纳斯达克：XOMA）（“XOMA”）的首席执行官和董事会成员，直至2023年1月退休。Neal先生于2009年加入XOMA，担任业务发展副总裁。在加入XOMA之前，Neal先生是Entelos，Inc.的代理首席执行官，Entelos，Inc.是一家领先的生物模拟公司。此前，在2007年，Entelos收购了Iconix Biosciences，这是一家私营公司，Neal先生担任首席执行官，并与百时美施贵宝、雅培实验室、礼来和美国食品药品监督管理局建立了多年的合作关系。1999年至2002年担任因塞特医疗基因组学执行副总裁期间，他领导了与制药公司合作者和合作伙伴的全球商业活动，包括辉瑞、安万特和先灵葆雅，以及公司的销售、市场营销和业务发展活动。早些时候，他与孟山都公司有关联，担任的职务越来越重。Neal先生还担任Akari Therapeutics的董事会成员，该公司是一家临床前阶段的生物制药公司。Neal先生在加拿大马尼托巴大学获得生物学学士学位和遗传学和植物育种硕士学位，并拥有密苏里州圣路易斯华盛顿大学的高级管理人员MBA学位。
James Neal has served as a director since July 2022. He brings more than 25 years of experience forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market. Mr. Neal served as the Chief Executive Officer and member of the board of directors of XOMA Corporation (Nasdaq: XOMA) ("XOMA") from December 2016 until his retirement in January 2023. Mr. Neal joined XOMA in 2009 as its Vice President, Business Development. Prior to joining XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos, Inc. a leading biosimulation company. Previously, in 2007, Entelos acquired Iconix Biosciences, a privately held company where Mr. Neal served as Chief Executive Officer and established multi year collaborations with Bristol Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration. While Executive Vice President of Incyte Genomics from 1999 to 2002, he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering Plough, as well as sales, marketing and business development activities for the company. Earlier, he was associated with Monsanto Company in positions of increasing responsibility. Mr. Neal also serves on the Board of Directors of Akari Therapeutics, a pre clinical stage biopharmaceutical company. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an Executive MBA degree from Washington University in St. Louis, Missouri. - James Neal自2022年7月起担任董事。他在全球范围内形成并最大限度地扩大业务和技术合作以及将新颖的产品和技术推向市场方面拥有超过25年的经验。Neal先生自2016年12月起担任XOMA公司（纳斯达克：XOMA）（“XOMA”）的首席执行官和董事会成员，直至2023年1月退休。Neal先生于2009年加入XOMA，担任业务发展副总裁。在加入XOMA之前，Neal先生是Entelos，Inc.的代理首席执行官，Entelos，Inc.是一家领先的生物模拟公司。此前，在2007年，Entelos收购了Iconix Biosciences，这是一家私营公司，Neal先生担任首席执行官，并与百时美施贵宝、雅培实验室、礼来和美国食品药品监督管理局建立了多年的合作关系。1999年至2002年担任因塞特医疗基因组学执行副总裁期间，他领导了与制药公司合作者和合作伙伴的全球商业活动，包括辉瑞、安万特和先灵葆雅，以及公司的销售、市场营销和业务发展活动。早些时候，他与孟山都公司有关联，担任的职务越来越重。Neal先生还担任Akari Therapeutics的董事会成员，该公司是一家临床前阶段的生物制药公司。Neal先生在加拿大马尼托巴大学获得生物学学士学位和遗传学和植物育种硕士学位，并拥有密苏里州圣路易斯华盛顿大学的高级管理人员MBA学位。
- James Neal has served as a director since July 2022. He brings more than 25 years of experience forming and maximizing business and technology collaborations globally and in bringing novel products and technologies to market. Mr. Neal served as the Chief Executive Officer and member of the board of directors of XOMA Corporation (Nasdaq: XOMA) ("XOMA") from December 2016 until his retirement in January 2023. Mr. Neal joined XOMA in 2009 as its Vice President, Business Development. Prior to joining XOMA, Mr. Neal was Acting Chief Executive Officer of Entelos, Inc. a leading biosimulation company. Previously, in 2007, Entelos acquired Iconix Biosciences, a privately held company where Mr. Neal served as Chief Executive Officer and established multi year collaborations with Bristol Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration. While Executive Vice President of Incyte Genomics from 1999 to 2002, he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering Plough, as well as sales, marketing and business development activities for the company. Earlier, he was associated with Monsanto Company in positions of increasing responsibility. Mr. Neal also serves on the Board of Directors of Akari Therapeutics, a pre clinical stage biopharmaceutical company. Mr. Neal earned his B.S. in Biology and his M.S. in Genetics and Plant Breeding from the University of Manitoba, Canada, and holds an Executive MBA degree from Washington University in St. Louis, Missouri.
- David Young
-
David Young，他是博士。他于2006年9月加入Processa Pharmaceuticals, Inc.的董事会，担任首席科学官。他于2009年10月被任命为首席科学官。担任Questcor公司执行官之前，他曾担任Processa Pharmaceuticals, Inc.董事会成员（从2006年9月到他退休）。他曾担任AGI Therapeutics公司的总裁（从2006年到2009年）。此前，他曾担任ICON公司（一个国际化合同研究组织（CRO））的战略药物开发部门的执行副总裁（从2003年到2006年），以及GloboMax公司（ICON公司于2003年收购的合同药物开发公司）的创始人兼首席执行官（从1997年到2003年）。创立GloboMax公司之前，他曾担任University of Maryland的药剂学院的副教授，在那里他曾担任一系列职务，包括药物动力学和生物药剂学实验室的董事、the University of Maryland-VA Clinical Research Unit的董事总经理。他持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的生理学学士学位、威斯康星大学麦迪逊分校（the University of Wisconsin - Madison）的医学物理学硕士学位、南加利福尼亚大学（the University of Southern California）的药学博士学位，以及the University of Southern California的制药科学博士学位。
David Young has served as Processa Pharmaceuticals, Inc.'s President, Research and Development and a director since August 8, 2023. He also served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer from October 4, 2017 until August 7, 2023, as the Chairman of Processa Pharmaceuticals, Inc.'s Board until July 11, 2022, and as Processa Pharmaceuticals, Inc.'s President from July 11, 2022 until August 8, 2023. As mentioned above, hist erm as a director will expire at this Annual Meeting. He has over 35 years of drug development experience serving as CEO, President and VP in different drug development companies. He served as Processa Pharmaceuticals, Inc.'s interim CFO from October 4, 2017 to September 1, 2018. From 2006 to 2014, Dr. Young served as a Questcor Pharmaceuticals Board Member and later as CSO, where he worked with FDA on the sNDA approval of Acthar for infantile spasms, an ultra rare orphan indication, and other indications. In 2014, Questcor was acquired for $5.7 billion. Dr. Young was previously an Associate Professor at the University of Maryland, has served on FDA Advisory Committees, and was involved with two FDA funded contracts as co principal investigator and investigator. Research from these contracts resulted in multiple FDA Guidances, which became the basis of Processa Pharmaceuticals, Inc.'s regulatory science approach to drug development. Dr. Young has served on NIH grant review committees and was Co Principal Investigator on an NCI contract to evaluate new oncology drugs. He has met with the FDA over one hundred times and has been a key member on more than thirty FDA indication approvals. Dr. Young received a B.S. in Physiology, M.S. in Medical Physics, and Pharm.D. Ph.D. specializing in pharmacokinetics pharmacodynamics. - David Young，他是博士。他于2006年9月加入Processa Pharmaceuticals, Inc.的董事会，担任首席科学官。他于2009年10月被任命为首席科学官。担任Questcor公司执行官之前，他曾担任Processa Pharmaceuticals, Inc.董事会成员（从2006年9月到他退休）。他曾担任AGI Therapeutics公司的总裁（从2006年到2009年）。此前，他曾担任ICON公司（一个国际化合同研究组织（CRO））的战略药物开发部门的执行副总裁（从2003年到2006年），以及GloboMax公司（ICON公司于2003年收购的合同药物开发公司）的创始人兼首席执行官（从1997年到2003年）。创立GloboMax公司之前，他曾担任University of Maryland的药剂学院的副教授，在那里他曾担任一系列职务，包括药物动力学和生物药剂学实验室的董事、the University of Maryland-VA Clinical Research Unit的董事总经理。他持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的生理学学士学位、威斯康星大学麦迪逊分校（the University of Wisconsin - Madison）的医学物理学硕士学位、南加利福尼亚大学（the University of Southern California）的药学博士学位，以及the University of Southern California的制药科学博士学位。
- David Young has served as Processa Pharmaceuticals, Inc.'s President, Research and Development and a director since August 8, 2023. He also served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer from October 4, 2017 until August 7, 2023, as the Chairman of Processa Pharmaceuticals, Inc.'s Board until July 11, 2022, and as Processa Pharmaceuticals, Inc.'s President from July 11, 2022 until August 8, 2023. As mentioned above, hist erm as a director will expire at this Annual Meeting. He has over 35 years of drug development experience serving as CEO, President and VP in different drug development companies. He served as Processa Pharmaceuticals, Inc.'s interim CFO from October 4, 2017 to September 1, 2018. From 2006 to 2014, Dr. Young served as a Questcor Pharmaceuticals Board Member and later as CSO, where he worked with FDA on the sNDA approval of Acthar for infantile spasms, an ultra rare orphan indication, and other indications. In 2014, Questcor was acquired for $5.7 billion. Dr. Young was previously an Associate Professor at the University of Maryland, has served on FDA Advisory Committees, and was involved with two FDA funded contracts as co principal investigator and investigator. Research from these contracts resulted in multiple FDA Guidances, which became the basis of Processa Pharmaceuticals, Inc.'s regulatory science approach to drug development. Dr. Young has served on NIH grant review committees and was Co Principal Investigator on an NCI contract to evaluate new oncology drugs. He has met with the FDA over one hundred times and has been a key member on more than thirty FDA indication approvals. Dr. Young received a B.S. in Physiology, M.S. in Medical Physics, and Pharm.D. Ph.D. specializing in pharmacokinetics pharmacodynamics.
高管简历
中英对照 | 中文 | 英文- George Ng
George Ng，自2020年2月起担任Legacy TuHURA董事，并在Kintara Merger合并完成后被任命为TuHURA董事会董事。Ng先生自2019年10月起担任Calidi Biotherapeutics， Inc. （NYSE American： CLDI）的董事，自2022年2月1日起担任其总裁兼首席运营官，以及自2023年8月8日起担任Processa Pharmaceuticals， Inc. （Nasdaq： PCSA）的董事兼首席执行官。此外，他目前是PENG Life Science Ventures的合伙人（2013年9月以来），IACTA Pharmaceuticals, Inc.的董事、联合创始人和首席商务官（2020年1月以来）。他的经验还包括在多家上市和私人全球生物技术和制药公司担任各种高管职位。Ng先生此前于2019年5月至2020年4月担任Inflammatory Response Research， Inc.董事，2019年7月至2020年1月担任Invent Medical Corp董事，2016年6月至2019年担任ImmuneOncia Therapeutics Inc.董事，并于2017年4月至2019年4月担任Virttu Biologics Limited董事。2015年3月至2019年4月，Ng先生还担任Sorrento Therapeutics， Inc.（纳斯达克股票代码：SRNE）的执行副总裁兼首席行政官；2012年9月至2019年4月，担任Scilex Pharmaceuticals Inc.的联合创始人兼业务总裁；2012年12月至2015年3月，担任BioDelivery Sciences International Inc.（纳斯达克股票代码：BDSI）的高级副总裁兼总法律顾问。他持有Notre Dame大学School of Law的法学博士学位，以及California大学， Davis的生物化学和经济学双学位。
George Ng has served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer and as a director since August 8, 2023. He has served as a member of the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi") from October 2019 to September 2024, and was Calidi's President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science Ventures since September 2013; a member of the board of directors and co founder at IACTA Pharmaceuticals, Inc. since January 2020; and member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020. His experience further includes serving in various executive level or board of director positions for multiple publicly traded and private global biotechnology and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co Founder and President, Business of Scilex Pharmaceuticals Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc. (Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis.- George Ng，自2020年2月起担任Legacy TuHURA董事，并在Kintara Merger合并完成后被任命为TuHURA董事会董事。Ng先生自2019年10月起担任Calidi Biotherapeutics， Inc. （NYSE American： CLDI）的董事，自2022年2月1日起担任其总裁兼首席运营官，以及自2023年8月8日起担任Processa Pharmaceuticals， Inc. （Nasdaq： PCSA）的董事兼首席执行官。此外，他目前是PENG Life Science Ventures的合伙人（2013年9月以来），IACTA Pharmaceuticals, Inc.的董事、联合创始人和首席商务官（2020年1月以来）。他的经验还包括在多家上市和私人全球生物技术和制药公司担任各种高管职位。Ng先生此前于2019年5月至2020年4月担任Inflammatory Response Research， Inc.董事，2019年7月至2020年1月担任Invent Medical Corp董事，2016年6月至2019年担任ImmuneOncia Therapeutics Inc.董事，并于2017年4月至2019年4月担任Virttu Biologics Limited董事。2015年3月至2019年4月，Ng先生还担任Sorrento Therapeutics， Inc.（纳斯达克股票代码：SRNE）的执行副总裁兼首席行政官；2012年9月至2019年4月，担任Scilex Pharmaceuticals Inc.的联合创始人兼业务总裁；2012年12月至2015年3月，担任BioDelivery Sciences International Inc.（纳斯达克股票代码：BDSI）的高级副总裁兼总法律顾问。他持有Notre Dame大学School of Law的法学博士学位，以及California大学， Davis的生物化学和经济学双学位。
- George Ng has served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer and as a director since August 8, 2023. He has served as a member of the board of directors of Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi") from October 2019 to September 2024, and was Calidi's President and Chief Operating Officer from February 1, 2022 until June 23, 2023. He has been a partner at PENG Life Science Ventures since September 2013; a member of the board of directors and co founder at IACTA Pharmaceuticals, Inc. since January 2020; and member of the board of directors of TuHURA Biosciences, Inc. (formerly, Morphogenesis, Inc.) since February 2020. His experience further includes serving in various executive level or board of director positions for multiple publicly traded and private global biotechnology and pharmaceutical firms. Mr. Ng previously served as a member of the board of directors of Inflammatory Response Research, Inc. from May 2019 to April 2020; Invent Medical Corp from July 2019 to January 2020; ImmuneOncia Therapeutics Inc. from June 2016 to 2019; and Virttu Biologics Limited from April 2017 to April 2019. He was also the Executive Vice President and Chief Administrative Officer of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) from March 2015 to April 2019; the Co Founder and President, Business of Scilex Pharmaceuticals Inc. from September 2012 to April 2019; and the Senior Vice President and General Counsel of BioDelivery Sciences International Inc. (Nasdaq: BDSI) from December 2012 to March 2015. Mr. Ng holds a JD degree from the University of Notre Dame School of Law, as well as a B.A.S. (B.A. and B.S.) dual degree in Biochemistry and Economics from the University of California, Davis.
- Patrick Lin
Patrick Lin自2017年10月4日起担任Processa Pharmaceuticals, Inc.首席业务与战略官，在生物制药领域拥有超过30年的融资和投资经验。他是Primarius Capital的创始人，并在超过15年的时间里担任管理合伙人，Primarius Capital是一家管理专注于小资本公司的公共和私人投资的家族办公室。在组建Primarius Capital之前的10年里，林先生曾在多家华尔街银行和经纪公司工作，包括Robertson Stephens & Co.，E*发售，与高盛 Sachs & Co. Lin先生为E的Co创始合伙人*提供。林先生获得了家乐氏管理研究生院的MBA学位、工程管理硕士学位以及南加州大学的学士学位。
Patrick Lin has served as Processa Pharmaceuticals, Inc.'s Chief Business & Strategy Officer since October 4, 2017 and has over 30 years of financing and investing experience in the Biopharm Sector. He is founder and, for more than 15 years, Managing Partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies. For 10 years prior to forming Primarius Capital, Mr. Lin worked at several Wall Street banking and brokerage firms including Robertson Stephens & Co., E*Offering, and Goldman Sachs & Co. Mr. Lin was Co Founding Partner of E*Offering. Mr. Lin received an MBA from Kellogg Graduate School of Management, an M.S. in Engineering Management, and a BS from the University of Southern California.- Patrick Lin自2017年10月4日起担任Processa Pharmaceuticals, Inc.首席业务与战略官，在生物制药领域拥有超过30年的融资和投资经验。他是Primarius Capital的创始人，并在超过15年的时间里担任管理合伙人，Primarius Capital是一家管理专注于小资本公司的公共和私人投资的家族办公室。在组建Primarius Capital之前的10年里，林先生曾在多家华尔街银行和经纪公司工作，包括Robertson Stephens & Co.，E*发售，与高盛 Sachs & Co. Lin先生为E的Co创始合伙人*提供。林先生获得了家乐氏管理研究生院的MBA学位、工程管理硕士学位以及南加州大学的学士学位。
- Patrick Lin has served as Processa Pharmaceuticals, Inc.'s Chief Business & Strategy Officer since October 4, 2017 and has over 30 years of financing and investing experience in the Biopharm Sector. He is founder and, for more than 15 years, Managing Partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies. For 10 years prior to forming Primarius Capital, Mr. Lin worked at several Wall Street banking and brokerage firms including Robertson Stephens & Co., E*Offering, and Goldman Sachs & Co. Mr. Lin was Co Founding Partner of E*Offering. Mr. Lin received an MBA from Kellogg Graduate School of Management, an M.S. in Engineering Management, and a BS from the University of Southern California.
- Wendy Guy
Wendy Guy自2017年10月4日起担任Processa Pharmaceuticals, Inc.首席行政官。她在企业运营、管理、合同、人力资源招聘、财务角色方面拥有超过20年的经验。2009年至2014年，Guy女士受雇于克斯克制药（2014年被马林克罗制药制药公司收购），担任Questcor马里兰州办事处负责业务运营的高级经理、业务运营。在Questcor工作的五年里，她建立了一支充满活力的行政和合同团队，将马里兰州办事处从两名员工扩大到略低于100人，并将设施从1,200平方英尺扩大到15,000平方英尺。在担任Questcor的职位之前，Guy女士是AGI Therapeutics，plc美国业务高级经理。在这个角色中，她负责公司的日常业务和行政运营。此前，她曾在ICON战略药物开发事业部、GloboMax、美世管理咨询公司担任多个高级职位。Guy女士获得了Mount Wachusett社区学院的A.A.。
Wendy Guy has served as Processa Pharmaceuticals, Inc.'s Chief Administrative Officer since October 4, 2017. She has over 20 years of experience in business operations, management, contracts, human resources recruiting, and finance roles. From 2009 to 2014, Ms. Guy was employed at Questcor Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals in 2014) as Senior Manager, Business Operations in charge of the Maryland Office for Questcor. During the five years she spent at Questcor, she built a dynamic administrative and contracts team, grew the Maryland Office from two employees to just under 100, and expanded the facility from 1,200 sq. ft. to 15,000 sq. ft. Prior to her position at Questcor, Ms. Guy was Senior Manager, U.S. Operations of AGI Therapeutics, plc. In this role, she was responsible for the day to day business and administrative operations of the company. Previously, she held multiple senior level positions with the Strategic Drug Development Division of ICON, GloboMax, and Mercer Management Consulting. Ms. Guy received an A.A. from Mount Wachusett Community College.- Wendy Guy自2017年10月4日起担任Processa Pharmaceuticals, Inc.首席行政官。她在企业运营、管理、合同、人力资源招聘、财务角色方面拥有超过20年的经验。2009年至2014年，Guy女士受雇于克斯克制药（2014年被马林克罗制药制药公司收购），担任Questcor马里兰州办事处负责业务运营的高级经理、业务运营。在Questcor工作的五年里，她建立了一支充满活力的行政和合同团队，将马里兰州办事处从两名员工扩大到略低于100人，并将设施从1,200平方英尺扩大到15,000平方英尺。在担任Questcor的职位之前，Guy女士是AGI Therapeutics，plc美国业务高级经理。在这个角色中，她负责公司的日常业务和行政运营。此前，她曾在ICON战略药物开发事业部、GloboMax、美世管理咨询公司担任多个高级职位。Guy女士获得了Mount Wachusett社区学院的A.A.。
- Wendy Guy has served as Processa Pharmaceuticals, Inc.'s Chief Administrative Officer since October 4, 2017. She has over 20 years of experience in business operations, management, contracts, human resources recruiting, and finance roles. From 2009 to 2014, Ms. Guy was employed at Questcor Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals in 2014) as Senior Manager, Business Operations in charge of the Maryland Office for Questcor. During the five years she spent at Questcor, she built a dynamic administrative and contracts team, grew the Maryland Office from two employees to just under 100, and expanded the facility from 1,200 sq. ft. to 15,000 sq. ft. Prior to her position at Questcor, Ms. Guy was Senior Manager, U.S. Operations of AGI Therapeutics, plc. In this role, she was responsible for the day to day business and administrative operations of the company. Previously, she held multiple senior level positions with the Strategic Drug Development Division of ICON, GloboMax, and Mercer Management Consulting. Ms. Guy received an A.A. from Mount Wachusett Community College.
- Russell Skibsted
Russell Skibsted自2024年7月16日起担任Processa Pharmaceuticals, Inc.的TERM1位首席财务官的TERM1位。他在医药行业拥有近30年的经验，包括财务管理、全球业务发展、资本筹集、投资者关系和运营方面的专业知识。他曾与处于各个发展阶段的公共和私营生命科学公司合作。最近，他担任Alimera医疗科学的高级副总裁兼首席财务官，该公司是一家全球眼科制药上市公司，于2023年1月至2023年12月期间被阿尼制药收购。在此之前，他于2020年9月至2022年11月在提供血液透析产品的上市公司罗克韦尔医药担任执行副总裁、首席财务官兼首席商务官。2017年7月至2020年5月，Skibsted先生担任BioTime的首席财务官，该公司是一家上市的生物技术公司，现名为Lineage Cell Therapeutics，他还曾在BioTime的几家公共和私营子公司担任不同时间的首席财务官，包括Agex Therapeutics、OncoCyte Corporation和海星生物治疗。在加入BioTime之前，Skibsted先生曾在多家公共和私营生命科学公司担任首席财务官或首席商务官，包括Aeolus Pharmaceuticals、光谱制药和Hana Biosciences。Skibsted先生拥有克莱蒙特麦肯纳学院的经济学学士学位和斯坦福大学商学院的MBA学位。
Russell Skibsted has served as Processa Pharmaceuticals, Inc.'s Chief Financial Officer since July 16, 2024. He has nearly 30 years of experience in the pharmaceutical industry including expertise in financial management, global business development, capital raises, investor relations and operations. He has worked with public and private life sciences companies at all stages of development. Most recently, he served as Senior Vice President and CFO of Alimera Sciences, a publicly traded global ophthalmic pharmaceuticals company that was acquired by ANI Pharmaceuticals from January 2023 to December 2023. Prior to that, he was Executive Vice President, CFO and Chief Business Officer at Rockwell Medical, a public company providing hemodialysis products from September 2020 to November 2022. From July 2017 to May 2020, Mr. Skibsted served as CFO of BioTime, a publicly traded biotechnology company now named Lineage Cell Therapeutics, where he also was CFO at various times for several of BioTime's public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation and Asterias Biotherapeutics. Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. Mr. Skibsted holds a BA in economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.- Russell Skibsted自2024年7月16日起担任Processa Pharmaceuticals, Inc.的TERM1位首席财务官的TERM1位。他在医药行业拥有近30年的经验，包括财务管理、全球业务发展、资本筹集、投资者关系和运营方面的专业知识。他曾与处于各个发展阶段的公共和私营生命科学公司合作。最近，他担任Alimera医疗科学的高级副总裁兼首席财务官，该公司是一家全球眼科制药上市公司，于2023年1月至2023年12月期间被阿尼制药收购。在此之前，他于2020年9月至2022年11月在提供血液透析产品的上市公司罗克韦尔医药担任执行副总裁、首席财务官兼首席商务官。2017年7月至2020年5月，Skibsted先生担任BioTime的首席财务官，该公司是一家上市的生物技术公司，现名为Lineage Cell Therapeutics，他还曾在BioTime的几家公共和私营子公司担任不同时间的首席财务官，包括Agex Therapeutics、OncoCyte Corporation和海星生物治疗。在加入BioTime之前，Skibsted先生曾在多家公共和私营生命科学公司担任首席财务官或首席商务官，包括Aeolus Pharmaceuticals、光谱制药和Hana Biosciences。Skibsted先生拥有克莱蒙特麦肯纳学院的经济学学士学位和斯坦福大学商学院的MBA学位。
- Russell Skibsted has served as Processa Pharmaceuticals, Inc.'s Chief Financial Officer since July 16, 2024. He has nearly 30 years of experience in the pharmaceutical industry including expertise in financial management, global business development, capital raises, investor relations and operations. He has worked with public and private life sciences companies at all stages of development. Most recently, he served as Senior Vice President and CFO of Alimera Sciences, a publicly traded global ophthalmic pharmaceuticals company that was acquired by ANI Pharmaceuticals from January 2023 to December 2023. Prior to that, he was Executive Vice President, CFO and Chief Business Officer at Rockwell Medical, a public company providing hemodialysis products from September 2020 to November 2022. From July 2017 to May 2020, Mr. Skibsted served as CFO of BioTime, a publicly traded biotechnology company now named Lineage Cell Therapeutics, where he also was CFO at various times for several of BioTime's public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation and Asterias Biotherapeutics. Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. Mr. Skibsted holds a BA in economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.
- David Young
David Young，他是博士。他于2006年9月加入Processa Pharmaceuticals, Inc.的董事会，担任首席科学官。他于2009年10月被任命为首席科学官。担任Questcor公司执行官之前，他曾担任Processa Pharmaceuticals, Inc.董事会成员（从2006年9月到他退休）。他曾担任AGI Therapeutics公司的总裁（从2006年到2009年）。此前，他曾担任ICON公司（一个国际化合同研究组织（CRO））的战略药物开发部门的执行副总裁（从2003年到2006年），以及GloboMax公司（ICON公司于2003年收购的合同药物开发公司）的创始人兼首席执行官（从1997年到2003年）。创立GloboMax公司之前，他曾担任University of Maryland的药剂学院的副教授，在那里他曾担任一系列职务，包括药物动力学和生物药剂学实验室的董事、the University of Maryland-VA Clinical Research Unit的董事总经理。他持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的生理学学士学位、威斯康星大学麦迪逊分校（the University of Wisconsin - Madison）的医学物理学硕士学位、南加利福尼亚大学（the University of Southern California）的药学博士学位，以及the University of Southern California的制药科学博士学位。
David Young has served as Processa Pharmaceuticals, Inc.'s President, Research and Development and a director since August 8, 2023. He also served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer from October 4, 2017 until August 7, 2023, as the Chairman of Processa Pharmaceuticals, Inc.'s Board until July 11, 2022, and as Processa Pharmaceuticals, Inc.'s President from July 11, 2022 until August 8, 2023. As mentioned above, hist erm as a director will expire at this Annual Meeting. He has over 35 years of drug development experience serving as CEO, President and VP in different drug development companies. He served as Processa Pharmaceuticals, Inc.'s interim CFO from October 4, 2017 to September 1, 2018. From 2006 to 2014, Dr. Young served as a Questcor Pharmaceuticals Board Member and later as CSO, where he worked with FDA on the sNDA approval of Acthar for infantile spasms, an ultra rare orphan indication, and other indications. In 2014, Questcor was acquired for $5.7 billion. Dr. Young was previously an Associate Professor at the University of Maryland, has served on FDA Advisory Committees, and was involved with two FDA funded contracts as co principal investigator and investigator. Research from these contracts resulted in multiple FDA Guidances, which became the basis of Processa Pharmaceuticals, Inc.'s regulatory science approach to drug development. Dr. Young has served on NIH grant review committees and was Co Principal Investigator on an NCI contract to evaluate new oncology drugs. He has met with the FDA over one hundred times and has been a key member on more than thirty FDA indication approvals. Dr. Young received a B.S. in Physiology, M.S. in Medical Physics, and Pharm.D. Ph.D. specializing in pharmacokinetics pharmacodynamics.- David Young，他是博士。他于2006年9月加入Processa Pharmaceuticals, Inc.的董事会，担任首席科学官。他于2009年10月被任命为首席科学官。担任Questcor公司执行官之前，他曾担任Processa Pharmaceuticals, Inc.董事会成员（从2006年9月到他退休）。他曾担任AGI Therapeutics公司的总裁（从2006年到2009年）。此前，他曾担任ICON公司（一个国际化合同研究组织（CRO））的战略药物开发部门的执行副总裁（从2003年到2006年），以及GloboMax公司（ICON公司于2003年收购的合同药物开发公司）的创始人兼首席执行官（从1997年到2003年）。创立GloboMax公司之前，他曾担任University of Maryland的药剂学院的副教授，在那里他曾担任一系列职务，包括药物动力学和生物药剂学实验室的董事、the University of Maryland-VA Clinical Research Unit的董事总经理。他持有加州大学伯克利分校（the Fisher Center Policy Advisory Board）的生理学学士学位、威斯康星大学麦迪逊分校（the University of Wisconsin - Madison）的医学物理学硕士学位、南加利福尼亚大学（the University of Southern California）的药学博士学位，以及the University of Southern California的制药科学博士学位。
- David Young has served as Processa Pharmaceuticals, Inc.'s President, Research and Development and a director since August 8, 2023. He also served as Processa Pharmaceuticals, Inc.'s Chief Executive Officer from October 4, 2017 until August 7, 2023, as the Chairman of Processa Pharmaceuticals, Inc.'s Board until July 11, 2022, and as Processa Pharmaceuticals, Inc.'s President from July 11, 2022 until August 8, 2023. As mentioned above, hist erm as a director will expire at this Annual Meeting. He has over 35 years of drug development experience serving as CEO, President and VP in different drug development companies. He served as Processa Pharmaceuticals, Inc.'s interim CFO from October 4, 2017 to September 1, 2018. From 2006 to 2014, Dr. Young served as a Questcor Pharmaceuticals Board Member and later as CSO, where he worked with FDA on the sNDA approval of Acthar for infantile spasms, an ultra rare orphan indication, and other indications. In 2014, Questcor was acquired for $5.7 billion. Dr. Young was previously an Associate Professor at the University of Maryland, has served on FDA Advisory Committees, and was involved with two FDA funded contracts as co principal investigator and investigator. Research from these contracts resulted in multiple FDA Guidances, which became the basis of Processa Pharmaceuticals, Inc.'s regulatory science approach to drug development. Dr. Young has served on NIH grant review committees and was Co Principal Investigator on an NCI contract to evaluate new oncology drugs. He has met with the FDA over one hundred times and has been a key member on more than thirty FDA indication approvals. Dr. Young received a B.S. in Physiology, M.S. in Medical Physics, and Pharm.D. Ph.D. specializing in pharmacokinetics pharmacodynamics.